- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Lupin Limited — Updates, 01-10-2025: Press Release
01-10-2025 | 03:02 pm
01-10-2025 | 03:02 pm
Lupin launched generic Rivaroxaban Oral Suspension (bioequivalent to Xarelto®) in the US, targeting pediatric VTE treatment. The original drug had estimated annual sales of USD 11 million, indicating a new market opportunity for Lupin.
No comments yet. Be the first to comment!